Cargando…
JMJD5 inhibits lung cancer progression by facilitating EGFR proteasomal degradation
Aberrant activation of epidermal growth factor receptor (EGFR) signaling is closely related to the development of non-small cell lung cancer (NSCLC). However, targeted EGFR therapeutics such as tyrosine kinase inhibitors (TKIs) face the challenge of EGFR mutation-mediated resistance. Here, we showed...
Autores principales: | Shen, Jing, Liu, Guiling, Qi, Hongyan, Xiang, Xueping, Shao, Jimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562424/ https://www.ncbi.nlm.nih.gov/pubmed/37813845 http://dx.doi.org/10.1038/s41419-023-06194-0 |
Ejemplares similares
-
JMJD5 links CRY1 function and proteasomal degradation
por: Saran, Anand R., et al.
Publicado: (2018) -
Correction: JMJD5 links CRY1 function and proteasomal degradation
por: Saran, Anand R., et al.
Publicado: (2019) -
JMJD8 Promotes Malignant Progression of Lung Cancer by Maintaining EGFR Stability and EGFR/PI3K/AKT Pathway Activation
por: Zhang, Bo, et al.
Publicado: (2021) -
ITCH facilitates proteasomal degradation of TXNIP in hypoxia‐ induced lung cancer cells
por: Sun, Qian, et al.
Publicado: (2022) -
PDE1 inhibition facilitates proteasomal degradation of misfolded proteins and protects against cardiac proteinopathy
por: Zhang, Hanming, et al.
Publicado: (2019)